Adeno-Associated Viral Vectors Market Poised for 17.6 % Growth, Set to Hit $9.41 Billion by 2029

How Are the key drivers contributing to the expansion of the adeno-associated viral vectors market?
The surging incidences of genetic disorders are set to spur the expansion of the adeno-associated viral vectors market. Genetic disorders result from DNA abnormalities in a person, causing either physical or developmental irregularities. The increase in these disorders is due to enhanced diagnostic procedures, heightened awareness, increased reproductive ages, environmental factors, and genetic drift. Adeno-associated viral vectors play a pivotal role in gene therapy for these disorders, introducings the necessary corrective genes into the targeted cells. This therapy has the potential to address conditions like muscular dystrophy or cystic fibrosis. For instance, in February 2023, the World Health Organization (WHO), a Switzerland-based specialized UN agency in charge of global public health, reported congenital diseases to be responsible for an estimated 240,000 newborn deaths worldwide within the first month of life annually, and an additional 170,000 deaths in children aged 1 month to 5 years. Hence, the escalating rate of genetic disorders is propelling the growth of the adeno-associated viral vectors market.

Get Your Adeno-Associated Viral Vectors Market Report Here:
https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

What growth opportunities are expected to drive the adeno-associated viral vectors market's CAGR through 2034?
The market size for adeno-associated viral vectors has seen swift expansion in the past few years. The projected growth is from $2.69 billion in 2024 to $3.17 billion in 2025, marking a compound annual growth rate (CAGR) of 17.9%. Contributing factors to this significant growth during the historical period include vaccine development, heightened funding and investment, collaborations between academia and industry, broadening of clinical trials, and heightened public awareness and advocacy.

The market for adeno-associated viral vectors is projected to experience swift expansion in the years to come, escalating to a value of $6.08 billion by 2029, presenting a compound annual growth rate (CAGR) of 17.6%. The predicted surge during this period can be credited to a broadening range of therapeutic applications, rising occurrence of genetic and neurological disorders, regulatory endorsements and backing, as well as a decrease in production costs. Key trends for this forecast period entail advancements in gene therapy, technological innovation, scalable production methods, collaborations and investments, and progress within technology itself.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp

What are the emerging trends shaping the future of the adeno-associated viral vectors market?
Leading firms in the adeno-associated viral vectors market are striving to gain a competitive advantage by providing easily accessible replication-capsid plasmid. These Rep/Cap plasmids, frequently used in gene therapy for producing adeno-associated virus (AAV) vector, can be obtained from a number of commercial providers satisfying the requirements of molecular biology research. For instance, in January 2024, Charles River Laboratories International Inc., a pharmaceutical company based in the US, launched a range of off-the-shelf replication-capsid plasmids that streamline AAV-based gene therapy efforts. This addition to their product line enhances their current lentiviral packaging and AAV Helper plasmid products, reducing manufacturing efforts by around 66%. These ready-to-use plasmids are produced in batches with thorough documentation, following CMC regulations and accompanied by a Certificate of Analysis (COA) to assist with IND and Clinical Trial Application (CTA) submissions.

Which growth-oriented segments of the adeno-associated viral vectors market are leading the industry's development?
The adeno-associated viral vectors market covered in this report is segmented -

1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies
2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas
4) By Scale Of Operation: Preclinical, Clinical, Commercial
5) By Application Area: Gene Therapy, Cell Therapy, Vaccines

Subsegments:
1) By Gene Augmentation: Inherited Genetic Disorders, Muscular Dystrophy, Cystic Fibrosis, Hemophilia
2) By Immunotherapy: Cancer Immunotherapy, Viral Infections Immunotherapy, Autoimmune Diseases Immunotherapy
3) By Other Types Of Therapies: Gene Editing, RNA Therapy, Antiviral Therapy

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15969

What regions are leading the charge in the adeno-associated viral vectors market?
North America was the largest region in the adeno-associated viral vectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What companies are at the forefront of innovation in the adeno-associated viral vectors market?
Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=15969&type=smp

What Is Covered In The Adeno-Associated Viral Vectors Global Market Report?

•Market Size Forecast: Examine the adeno-associated viral vectors market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the adeno-associated viral vectors market for a structured understanding.
•Key Players Overview: Analyze major players in the adeno-associated viral vectors market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the adeno-associated viral vectors market.
•Segment Contributions: Evaluate how different segments drive overall growth in the adeno-associated viral vectors market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the adeno-associated viral vectors market.
•Industry Challenges: Identify potential risks and obstacles affecting the adeno-associated viral vectors market.
•Competitive Landscape: Review strategic developments in the adeno-associated viral vectors market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.